LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

LLY

1,028

-1.37%↓

JNJ

245.17

-0.42%↓

ABBV

226.93

-0.59%↓

NVS

166.41

-0.16%↓

MRK

122.41

-1.23%↓

Strona główna・Stock List・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Closed

SectorHealthcare

24.78 2.48

Buy Sell

Overview

Share price change

24h

Current

Min

24.06

Max

24.97

Key metrics
By Trading Economics
Income	675K 53M
Sales	1.8M 148M
P/E Sector Avg	14.099 108.767
Profit margin	35.57
Employees	181
EBITDA	1.7M 80M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+44.69% upside

Dividends
By Dow Jones
Next Earnings	6 maj 2026

Market Stats
By TradingEconomics
Market Cap	339M 3B
Previous open	22.3
Previous close	24.78

News Sentiment

By Acuity

100%

337 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

N/A / 24.28 Support & Resistance

Catalyst Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

25 lut 2026, 23:25 UTC

Hot Stocks

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 lut 2026, 23:15 UTC

Earnings

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 lut 2026, 23:54 UTC

Market Talk

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 lut 2026, 23:47 UTC

Earnings

Ferrovial 4Q Net EUR197M >FER.MC

25 lut 2026, 23:45 UTC

Earnings

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 lut 2026, 23:42 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 lut 2026, 23:38 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Company's Business Operations Remain Normal >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 lut 2026, 23:25 UTC

Earnings

Trip.com FY EPS CNY47.67 >TCOM

25 lut 2026, 23:06 UTC

Earnings

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 lut 2026, 23:01 UTC

Earnings

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 lut 2026, 23:00 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

25 lut 2026, 23:00 UTC

Market Talk

Earnings

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 lut 2026, 22:56 UTC

Market Talk

Earnings

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 lut 2026, 22:43 UTC

Earnings

Acquisitions, Mergers, Takeovers

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 lut 2026, 22:40 UTC

Market Talk

Earnings

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 lut 2026, 22:40 UTC

Earnings

Karoon Energy Says Search for New CFO Well Advanced

25 lut 2026, 22:39 UTC

Earnings

Karoon Energy Says CFO Ray Church to Leave Company

25 lut 2026, 22:39 UTC

Earnings

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 lut 2026, 22:38 UTC

Earnings

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Peer Comparison

Price change

Catalyst Pharmaceuticals Inc Forecast

Price Target

By TipRanks

44.69% upside

12 Months Forecast

Average 35 USD 44.69%

High 35 USD

Low 35 USD

Based on 1 Wall Street analysts offering 12 month price targets forCatalyst Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Catalyst Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 24.28Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

337 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.